NKTR
Nektar Therapeutics
$75.33
▲ 2.3%Updated Today 11:10 AM ET
NKTR at a glance — five pillars scored 0–100 from real filed financials.
Overall: Unrated · 0/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Market Cap
$0.00
P/E
—
Forward P/E (est.)
—
ROE
—
Revenue Growth
—
EPS Growth
—
Profit Margin
—
FCF Yield
—
Debt / Equity
—
ROIC
-11.0%
Interest Coverage
—
Current Ratio
10.42x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
0/100
Nektar Therapeutics (NKTR) is a small-cap company in the Pharmaceuticals industry, part of the Health Care sector of the S&P 500.
In its latest reported year it generated about $55.23M in revenue and posted a net loss of $164.08M.
Our model rates NKTR Unrated (0/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Evidence of durable competitive advantage in the filed financials (10 years of history).
The numbers don't show a durable competitive advantage — margins, growth, or returns on capital have been unstable or thin. Great returns are still possible; they just aren't protected.
-217.7% average over the last 3 years
±165.2 pts around -219.1% across 10 years
grew in 4 of the last 9 year-over-year periods
positive in 1 of 10 years
-11.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
4Y CAGR
-14.2%
Revenue moved from $165.44M in 2016 to $55.23M in 2025, a -11.5% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.
Gross Margin
—
Operating Margin
-253.7%
Net Margin
-297.1%
ROE
—
Total Debt
$133.50M
Net Debt
$94.23M
Net Debt / EBITDA
—
Debt / Equity
—
Leverage: debt-to-equity is n/a, with a current ratio of 10.4x. Detailed balance-sheet leverage is limited for this name. It carries roughly $133.50M of total debt against $39.27M of cash.
Operating CF
-$208.51M
Free Cash Flow
-$208.68M
FCF Margin
-377.8%
In the latest year Nektar Therapeutics produced about -$208.51M of operating cash flow but negative free cash flow as it invested heavily. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
—
P/S
—
P/B
—
EV / EBITDA
—
NKTR trades at n/a trailing earnings. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.
Where NKTR sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How NKTR stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), NKTR ranks #232 of 324 by our overall rating.
P/E vs sector
—
median 27.3x
ROE vs sector
—
median 14.1%
Growth vs sector
—
median 7.6%
Sector rank
#232
of 324 by rating
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $75.33 today · expected CAGR -59% – -55%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $59.65M | $64.42M | $69.58M | $75.14M | $81.15M |
| Net income | $1.79M | $1.93M | $2.09M | $2.25M | $2.43M |
| EPS | $0.05 | $0.06 | $0.06 | $0.07 | $0.07 |
| Share price (low) | $0.63 | $0.68 | $0.73 | $0.79 | $0.86 |
| Share price (high) | $1.05 | $1.13 | $1.22 | $1.32 | $1.43 |
| CAGR (low–high) | -99% / -99% | -91% / -88% | -79% / -75% | -68% / -64% | -59% / -55% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for NKTR:
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against NKTR:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Nektar Therapeutics is a small-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at n/a earnings, which our model scores Unrated (0/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 17 Wall Street analysts covering NKTR recommend (August 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Latest SEC Filings
NKTR's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
NKTR — frequently asked questions
Is NKTR a good stock to buy?
We don't give buy or sell advice. Review Nektar Therapeutics's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.
Where does NKTR's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Nektar Therapeutics's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for NKTR calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this NKTR analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell NKTR. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.